Table 2 Association of CCND1 rs9344 with cancer susceptibility and clinical outcomes in patients received platinum-based chemotherapy

Susceptiblity^a

Case

Control

1.115(0.869–1.431)

0.391

0.980(0.673–1.425)

0.914

1.498(0.935–2.399)

0.0927

GG

127(25.5)

33(15.5)

GA

237(47.6)

106(49.8)

AA

126(25.3)

72(33.8)

Chemotherapy response^b

Responder

Non-responder

1.225(0.934–1.607)

0.142

1.274(0.848–1.914)

0.243

1.375(0.838–2.255)

0.207

GG

31(16.8)

61(21.6)

GA

85(46.2)

134(47.3)

AA

67(36.4)

85(30.0)

Overall toxicity^b

Grade 0–2

Grade 3–4

1.142(0.874–1.493)

0.33

1.110(0.736–1.674)

0.618

1.323(0.824–2.125)

0.246

GG

51(17.8)

41(22.7)

GA

137(47.9)

83(45.9)

AA

94(32.9)

57(31.5)

Gastrointestinal toxicity^b

Grade 0–2

Grade 3–4

1.048(0.767–1.432)

0.768

1.034(0.636–1.679)

0.894

1.109(0.641–1.920)

0.711

GG

69(18.9)

23(22.8)

GA

175(47.8)

45(44.6)

AA

118(32.2)

33(32.7)

Hematological toxicity^b

Grade 0–2

Grade 3–4

1.012(0.749–1.366)

0.94

0.965(0.611–1.523)

0.878

1.090(0.639–1.859)

0.751

GG

69(19.5)

23(20.2)

GA

167(47.3)

53(46.5)

AA

113(32.0)

38(33.3)